Method for treating cancer

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with complex therapy of mammary gland cancer at T1-2NO-1MO. The method includes chemo- and radiation therapy and operation procedure. Moreover, in post-surgical period, before the onset of radiation therapy course it is necessary to sample 200 ml patient's blood and due to centrifuging technique isolate autoplasma. One should place 20 ml autoplasma and chemopreparations into the first vial, into the second vial - remained blood cells and autoplasma. Vials should be separately incubated for 40 min at 37° C, then during the first day of radiation therapy before the onset of the seance one should introduce the half of autoplasma volume incubated with chemopreparations from the first vial into the ducts of operated mammary gland, as for the remained part of autoplasma incubated with chemopreparations, from the first vial it should be introduced into the site of surgical withdrawal of drainage tube. Blood incubated with chemopreparations from the second vial should be reinfused intravenously by drops. The innovation is of low toxicity and enables to carry out complex organ-saving therapy in short terms, decrease the frequency of local relapses and remote metastases, the number of radiation reactions and complications.

EFFECT: higher efficiency.

2 ex

 

The invention relates to medicine, namely to Oncology, and can be used in treatment of cancer, prevention prevention of the incidence of recurrence and metastasis of cancer, in particular when organochromium the treatment of breast cancer T1-2N0-M.

Known high incidence of recurrence and distant metastasis after application of the primary surgical treatment of malignant solid tumors (see Snesko LI Prevention of recurrence and metastasis of colon cancer. L., 1976. 176 C.). During surgery for malignant neoplasms is inevitable trauma of the tumor, which leads to the dissipation of tumor cells through the blood, lymphatic system, increases the number of tumor cells in regional veins zone of the tumor and in the General circulation. The decrease in the total body resistance caused by surgery, injury to organs during surgery leads to intensification of processes of metastasis and recurrence.

Known "Method of neoadjuvant autolackiererei when treating patients with locally advanced breast cancer (see Vladimirov LU Neoadjuvant chemotherapy on the natural environment of the organism with the use of the peptide of the epiphysis of epithalamin in treatment of locally advanced location is defamiliarised breast cancer: author. dis. ... candles. the honey. Sciences. Rostov-n/a, 2000). Patients with locally advanced breast cancer conducted neoadjuvant autolackiererei standard chemotherapy in the conventional course doses.

Shows the higher efficiency of autolackiererei compared with autohemotherapy and systemic chemotherapy in the number of cases of complete and partial clinical regression of the tumor and lymph nodes, the number of cases of disease progression, improvement in 2-year overall survival. Improved the immediate results of the treatment. However, duration of recurrence-free period was insignificant, and information about metastasis are not tracked and are not presented.

Thus, improved immediate outcomes of treatment. However, increased frequency and severity of toxic reactions compared with autohemotherapy, the method is only used for preoperative preparation of the patient, will not increase the effectiveness of subsequent radiation therapy.

Known "Method of treatment of breast cancer" (Makidon VA et al. Comprehensive preoperative treatment when performing economical operations in patients with breast cancer // proceedings of the 1st Congress of oncologists of CIS, 3-6 December 1996, Moscow. S.), chosen as a prototype. The way is to follow what you eat for 3 days before surgery daily radiation therapy at a dose of 6 Gy to the breast, axillary and infraclavicular lymph nodes. 3 hours after radiation therapy on the first day of the tumor bed infiltrate cyclophosphamide at a dose of 1 g/m2on the second day - methotrexate 50 mg/m2on the third day - thiotepa 40 mg/m2. Then the tumor is subjected to local microwave hyperthermia. On the 4th day of treatment perform economical resection of breast cancer. In the postoperative period spend chemo-and radiotherapy. The paper does not present results of treatment, data on the number of relapses and metastases of cancer.

The aim of the invention is to reduce the incidence of local recurrence and metastases after combined organ-preserving treatment of breast cancer.

This objective is achieved in that in the postoperative period, before the start of radiation therapy in patients taking 200 ml of blood by centrifuging of the blood allocate autoplasma in the first vial was placed 20 ml of autoplasma and chemotherapy, the second bottle is the remainder of the formed elements of blood, plasma, separately incubated bottles for 40 minutes at 37°C. Then on the first day of radiation therapy, before the start of the session in the ducts of the operated breast cancer injected half of the total incubated autoplasma with chemotherapy drugs from the first bottle (using the standard method of ductography breast cancer). the remaining part of the incubated autoplasma with chemotherapy drugs from the first vial is injected through contraportada in the underarm area (site removal of the drainage tube during surgery). Incubated blood from the second vial is re-infused intravenous drip.

The invention is a Method of treatment of cancer" is new, because it is unknown in the field of medicine in surgical and chemotherapeutic treatment of malignant tumors, prevention of local recurrence and distant metastasis of breast cancer.

The novelty of the invention lies in the fact that in the postoperative period, before the start of radiation therapy in patients taking 200 ml of blood by centrifuging of the blood allocate autoplasma in the first vial was placed 20 ml of autoplasma and chemotherapy, the second bottle is the remainder of the formed elements of blood, plasma, separately incubated bottles for 40 minutes at 37°C. Then on the first day of radiation therapy, before the start of the session in the ducts of the operated breast cancer injected half of the total incubated autoplasma with chemotherapy drugs from the first bottle (using the standard method of ductography breast cancer). The remainder incubated autoplasma with chemotherapy drugs from the first vial is injected through contraportada in the underarm area (site removal of the drainage tube during surgery). Incubated blood from the second vial reinfurt intravenous drip.

Thus, postoperative local chemotherapy on autoplasma in PR the current system of the breast and axillary region helps prevent incidence of recurrence and metastasis in breast cancer, increases the effectiveness of radiation therapy, reinfuse autologous blood reduces the amount of radiation reactions and complications.

The invention "Method of cancer treatment is industrially applicable, as may be used in health care, hospitals cancer profile, dispensaries, cancer research institutes.

Examples of specific application "method of cancer treatment on patients.

App.1. Patient Strusinska L.V., 1953, history 4384/R, was admitted to the Department of General Oncology, RNII 26.3.03.

From the anamnesis: the tumor in the left breast was found 2 months ago, asked for medical help in RNII 25.03.03. During the examination in the clinic, RNII made a puncture of the tumor of the left breast. Cytological analysis No. 453-54: groups of carcinoma cells. Diagnosed with breast cancer, stage 2, clinical group 2" patient hospitalized in the Department of General Oncology.

Admission: in the upper outer quadrant of the left breast is dense, without clear borders of the tumor up to 2.5 cm in diameter. Regional lymph nodes are not enlarged.

28.03.03 operation performed radical resection of the left breast. Postoperative histological analysis 685428-29: infiltrating ductal cancer; 686059-69: lymph node metastasis of the cancer. Paleoposition the initial diagnosis of breast cancer, T2N1M0, stage 2, clinical group 2.

The postoperative period was uneventful, with no complications. Sutures were removed on the 12th day. On the 13th day, the patient was taken 200 ml of autologous blood, centrifuging of the blood dedicated autoplasma in the first vial was placed 20 ml of autoplasma and 500 mg of 5-fluorouracil 400 mg of cyclophosphamide, the second bottle is the remainder of the formed elements of blood plasma. Separately incubated bottles for 40 minutes at 37°With, then on the first day of radiation therapy, before the start of the session in the ducts of the operated breast cancer entered the half volume of the incubated autoplasma with chemotherapy in the first vial, using a standard method of ductography breast cancer. The remainder incubated autoplasma with chemotherapy drugs from the first vial is entered through contrapartida, in place of removing the drainage tube during surgery. Incubated blood from the second vial reinfusion intravenous drip.

Patients received a course of distance gamma-therapy apparatus agate R" for the rest of the left mammary gland, axillary, nepodklyuchen, parasternal field in 2 Gy daily, 5 fractions per week (a total of 20 fractions). Total focal dose was 40 Gy. The level of leukocytes, peripheral blood lymphocytes was reduced; abnormalities in the biochemical blood analysis, urinalysis n what it was.

The patient was discharged in satisfactory condition. When houses in RNII within 2 years after treatment data for recurrence and metastases are detected. Feeling sick satisfactory cosmetic effect is assessed as excellent.

PR. Patient Girin CENTURIES, 1951, history 6877/R, was admitted to the Department of General Oncology, RNII 25.04.03.

From the anamnesis: the tumor in the right breast was found 1 month ago, sought medical help from a doctor at the place of residence, sent to RNII diagnosed with a tumor of the right breast. During the examination in the clinic, RNII made a puncture of the tumor of the left breast. Cytological analysis No. 986: usernotification carcinoma. Diagnosed with cancer of the right breast, stage 1, clinical group 2" patient hospitalized in the Department of General Oncology.

On arrival at the border of the outer quadrants of the right breast is dense, without clear borders of the tumor up to 1.5 cm in diameter. Regional lymph nodes are not enlarged.

28.04.03 operation performed radical resection of the right breast. Postoperative histological analysis 690732: infiltrating ductal cancer; 690874-79: in axillary lymph nodes metastases of cancer. Postoperative diagnosis: cancer of the right breast, T1N1M0, phase 2, clinical group 2.

Poslove the sure period was uneventful, without complications. Sutures were removed on the 11th day. For 12 hours, the patient is taken 200 ml of autologous blood, centrifuging of the blood dedicated autoplasma in the first vial was placed 20 ml of autoplasma and 500 mg of 5-fluorouracil 400 mg of cyclophosphamide, the second bottle is the remainder of the formed elements of blood plasma. Separately incubated bottles for 40 minutes at 37°With, then on the first day of radiation therapy, before the start of the session in the ducts of the operated breast cancer entered the half volume of the incubated autoplasma with chemotherapy in the first vial, using a standard method of ductography breast cancer. The remainder incubated autoplasma with chemotherapy drugs from the first vial is entered through contrapartida, in place of removing the drainage tube during surgery. Incubated blood from the second vial reinfusion intravenous drip.

Patients received a course of distance gamma-therapy apparatus agate R" for the rest of the right mammary gland, axillary, nepodklyuchen, parasternal field in 2 Gy daily, 5 fractions per week (a total of 20 fractions). Total focal dose was 40 Gy. The level of leukocytes, peripheral blood lymphocytes was reduced; abnormalities in the biochemical blood analysis, urinalysis was not.

The patient was discharged in satisfactory condition. When houses in RNII in ECENA 2 years after treatment data for recurrence and metastases are detected. Feeling sick satisfactory.

The proposed method treated 10 patients with breast cancer T1-2N0-1M0. The use of postoperative local chemotherapy for autologous environments of an organism simultaneously with radiation therapy does not cause changes in General, the biochemical analysis of blood, improves the General condition of patients, is characterized by low toxicity, does not violate processes postoperative wound healing. Patients traced in the interval from 6 months to 2 years. During the observation period did not reveal a single case of local recurrence or distant metastasis.

Technical and economic efficiency "treatment of cancer" is that the method allows to reduce the incidence of local recurrence and distant metastases, low toxicity, increases the effectiveness of radiation therapy reduces the frequency of radiation reactions and complications, simple in execution. The method allows for comprehensive treatment in a short time, parallel to the surgery, reduces the duration of stay of the patient in hospital and the cost of treatment of recurrent and metastatic breast cancer.

A method of treating breast cancer, including chemotherapy and radiation therapy, surgery, characterized in that in the postoperative period until the beginning of the course of radiation is FIPA patient taking 200 ml of blood, by centrifuging allocate autoplasma in the first vial was placed 20 ml of autoplasma and chemotherapy, the second bottle is the remainder of the formed elements of blood and autoplaza, separately incubated bottles for 40 min at 37°With, then on the first day of radiation therapy before the start of the session introduce the half volume of autoplasma, incubated with chemotherapy, from the first vial in the ducts of the operated breast cancer, and the remaining part of autoplasma, incubated with chemotherapy, from the first vial is injected in place of the surgical removal of the drainage tube, incubated with chemotherapy drugs, blood from the second vial is re-infused intravenous drip.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method involves introducing photosensitizer of photosense at a dose of 0.1-1.0 mg/kg of patient weight. Photodynamic therapy is applied in 48-72 h with laser radiation at wavelength of 675 nm after having introduced the photosense. Iradiation is carried out in transscleral way after having determined tumor base projection place over sclera in transillumination way. Exposure dose is equal to 80-800 mW/cm2 with cylindrical light guide set at a distance from sclera that laser radiation beam diameter overlaps tumor base diameter by 1-2 mm at its projection place on sclera.

EFFECT: enhanced effectiveness of treatment.

FIELD: medicine.

SUBSTANCE: method involves mixing patient liquor with 3 ml of 10% albumin solution, with chemopreparation and incubating. Then, the mixture is introduced via catheter into subarchnoid space. Repeated introduction is carried out 7 days later.

EFFECT: alleviated intracranial hypertension phenomena in cases of endolumbal drugs introduction; reduced risk of toxic complications.

FIELD: medicine.

SUBSTANCE: method involves introducing water-soluble chemopreparation as a course in lymphotropic way. Riva-Rocci apparatus cuff is applied to lower part of femur and pressure of 40 mm of mercury column is created. 20 ml of chymotrypsin dissolved in 0.5% Novocain solution is subcutaneously introduced into the middle area of lateral shank surface 30 min later. Water-soluble chemopreparations are slowly subcutaneously introduced 0.5 cm below the chymotrypsin injection place in 5-7 min as single dose. The cuff is left in swollen state for 2 h. After having taken off the cuff, 50 ml of 0.5% Novocain solution is subcutaneously introduced into the place of previous water-soluble chemopreparations injection. Then the lower extremity is dressed with elastic bandage. The lymphotropic water-soluble chemopreparations introduction procedure is carried out once a day combined with standard chemotherapy course. Detralex is daily given to the patient on the background of the chemotherapy course at a dose of 2 pills twice a day combined with subcutaneous Fraxiparin injections introduced at a dose of 0.3 ml once a day.

EFFECT: avoided surgical intervention; increased antitumor effectiveness; reduced risk of recurrences, metastases and toxic complications.

5 dwg

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with treating metastatic hepatic disorder in patients with malignant neoplasms. The method of regional polychemotherapy (RPCT) concentrates upon catheterization of proper hepatic artery (PHA) through gastro-omental artery to fulfill intra-arterial RPCT. Moreover, additionally after PHA catheterization it is necessary to catheterize an umbilical vein (UV) due to fulfilling arterio-venous shunting. For this purpose, one should connect catheters introduced into UV and PHA, with the help of a T-joint valve appliance (TVA); before carrying out RPCT it is important to conduct hepatic arterialization due to directing the blood from PHA through UV into the liver by setting TVA valves in position being open for PHA and UV; for carrying out RPCT one should locate TVA valves in position being open for introducing chemopreparations out of the system with a dosing tank of medicinal substances into PHA to carry out the infusion of chemopreparations. Seances for alternating hepatic arterialization and RPCT should be fulfilled daily once a day during the whole course of therapy. The innovation enables to simultaneously increase the concentration of chemopreparations in metastatic hepatic foci, detoxication hepatic function and sensitivity of tumor cells to chemopreparations as a result of additional preliminary oxygenation of hepatocytes.

EFFECT: higher efficiency of therapy.

1 cl, 6 dwg, 1 ex

FIELD: medicine, prophylactic oncology, pharmacy.

SUBSTANCE: invention proposes an agent belonging to class of nonsteroid anti-inflammatory preparations, namely, associate comprising 2[(2,6-dichlorophenyl)amino]-benzene acetic acid, inosine and N-methylglucosamine. In oral administration this associate inhibits effectively origination and development of malignant and benign tumors of brain, spinal cord, kidneys, breast, esophagus, forestomach, uterus cervix and vagina induced by chemical carcinogens in laboratory animals. Invention provides preparing the preparation possessing the more expressed anti-carcinogenic activity and lesser toxic ulcerous effect.

EFFECT: improved and valuable medicinal properties of agent.

5 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: method involves taking blood sample into sterile flask in the amount of 150 ml before and after funiculo-orchectomy. Plasma and formed elements are separated by means of centrifuging. Plasma is taken and 300 mg Bleocin and 1000 mg Cyclophosphane are dissolved in a portion of it. Platinum preparation is added to the plasma and formed elements remaining in the flask in the amount of 75-100 mg/m2. When completely dissolved, the produced solutions are incubated in thermostat at 37°C during 40 min. Endolymphatic infusion of preparations on patient autoplasma is carried out into lymphatic vessel of foot back on the side where tumor process takes place, and intravenous autohemochemotherapy with platinum preparations are sequentially carried out under hyperhydration and forced diuresis conditions.

EFFECT: concentrated purposeful action upon primary testicular carcinoma and metastases into retroperitoneal lymph nodes; reduced risk of toxic complications.

FIELD: medicine, oncology.

SUBSTANCE: in patients with prognostically unfavorable laryngeal and pharyngeal cancer therapy should be started with carrying out chemotherapy with preparations that enhance radiation action. Local hyperthermia should be conducted twice weekly at the background of radiation therapy. Moreover, during hyperthermal days a single focal dosage corresponds to 4 Gy - 2 Gyx2 at 4-h-long interval. The innovation enables to increase efficiency in treating patients with cerebral and cervical squamous cell cancer stage III-IV, improve viability values in this category of patients, decrease toxicity and improve therapeutic results at acceptable increase of topical radiation alterations and hematological toxicity.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine.

SUBSTANCE: method involves administering Wobenzyme combined with brachytherapy with radiomodification and transpupillary thermotherapy or combined with isolated transpupillary thermotherapy. When combined with brachytherapy with radiomodification, Wobenzyme is given 2 days before brachytherapy at a dose of 3 pills 3 times a day with the exception of 8 h before fixation and removal of β-applicator. Next to it, Wobenzyme is given at a dose of 4-6 pills 3 times a day during 3 months. Then, the dose is reduced by 2 pills every month at the fourth, fifth and sixth months. Adjuvant transpupillary thermotherapy is carried out 6 months later after brachytherapy. Wobenzyme is given at a dose of 2-3 pills 3 times a day 2 days before transpupillary thermotherapy. Then, the dose is 4-6 pills 3 times a day during 2 months with following dose reduction by 3 pills every month to prophylactic dose of 1 pill a day. When carrying out isolated transpupillary thermotherapy, Wobenzyme is given in the same mode that it was the case when carrying out adjuvant transpupillary thermotherapy after brachytherapy. To prevent metastasis occurrence, Wobenzyme administration is continued at a dose of 1 pill 7 days every month during the first year and at a dose of 1 pill 3 days every month during the second observation year.

EFFECT: accelerated resorption processes; reduced risk of radiation treatment complications.

FIELD: oncology.

SUBSTANCE: treatment consists in performing 2-4 courses of preoperative chemotherapy with 2-weak intervals between courses, each course comprising intravenous administration of methotrexate in dose 40 mg/m2 on first or eighth day and intramuscular cyclophosphanin dose 100 mg/m2 during 14 days, while introducing additionally oral Xeloda in dose 1000 mg/m2 twice a day on the first to fourteenth days.

EFFECT: achieved complete regression of tumor focus owing to high selectivity of Xeloda preparation diminishing toxic effect of chemotherapy.

3 ex

FIELD: organic chemistry, medicine, oncology, pharmacy.

SUBSTANCE: invention relates to novel C-2'-methylated derivatives of paclitaxel of the formula (I): wherein R represents trifluoromethyl group, phenyl, 2-furyl, 2-thienyl; R1 represents tert.-butoxycarbonyl or benzoyl group; R2 represents hydroxy-group; R3 means hydrogen atom or in common with R2 forms residue of cyclic carbonate of the formula: under condition that when R3 means hydrogen atom then R is not phenyl. Also, invention relates to a pharmaceutical composition based on thereof and using for preparing medicinal agents possessing an antitumor activity. Invention provides preparing novel derivatives of paclitaxel that possess antitumor activity.

EFFECT: valuable medicinal property of derivatives and pharmaceutical composition.

4 cl, 1 tbl, 6 ex

FIELD: methods and devices for treatment of oncology patients using sources of ionizing radiation, namely, technology of pre-irradiation preparation and irradiation during intracavitary and interstitial radiotherapy.

SUBSTANCE: method for pre-irradiation preparation and irradiation includes positioning the patient on treatment-diagnostics table, inserting into cavity to be irradiated of hollow applicators with imitators of ionizing radiation sources, controlling position thereof relatively to target being irradiated with usage of x-ray television device, building of dosimetric plane and irradiation, while applicators inserted into cavity being irradiated are connected to treatment-diagnostics table, x-ray radiography is performed with output of image onto monitor of viewing station of x-ray television device, image via the interface is transported into planning system, dosimetric plane of irradiation is computed, which is then exported into system for controlling device and irradiation procedure is performed. Treatment-diagnostics table has frame, two supporting posts with overhung table top mounted on them, consisting of a pelvic-dorsal and two extending leg sections, connected to pelvic-dorsal section by means of twin joints. For connection of applicator table is provided with mounting pillar.

EFFECT: possible irradiation directly near apparatus without moving the patient during x-ray control of position of applicators and, therefore, increased quality of radiotherapy and therapeutic efficiency, decreased duration of pre-irradiation preparation.

2 cl, 3 dwg

FIELD: medicine, in particular, radiotherapy.

SUBSTANCE: during irradiation of oncology patients on cobalt distance apparatuses dose field is formed by injecting topographic-anatomic information of patient into dose planning system and generating with its consideration of main dose field on basis of results of calculations of main dose field, dose deficiency area is located within limits of target and iso-centers of additional dose fields are positioned therein, while width of radiation beams, generating additional dose fields, is less than width of beam of main dose fields 1,5-2,5 times, while value of dose of main field is 0,7-0,85 of resulting dose within limits of target.

EFFECT: possible generation of dose field with minimal possible dose change on target while simultaneously decreasing radiation loads on normal tissues and skin.

2 dwg, 1 ex

FIELD: medicine, in particular, oncology.

SUBSTANCE: in accordance to method, thermo-radio-therapy of malignant tumors is performed in form of split course in mode of enlarged dynamic fractioning of dose in 6 fractions of 4 Gy and 8 fractions of 2 Gy in first course, and 6 fractions of 4 Gy and 3 fractions of 2 Gy in second course in conjunction with hyper-thermal effect in the same day when radio-therapy is performed.

EFFECT: increased apparent counter-tumor local effect.

2 ex

FIELD: medicine, namely, medicinal use of radiation, possible use for determining dose really received by pathologic focus having absorbed open radioactive nuclide.

SUBSTANCE: method for verification of dose during medicinal usage of open radioactive nuclides includes measuring intensiveness of radiation, with consideration of changes in radiation source activity in time, during that, by means of tissue-equivalent phantom, original intensiveness of radiation of open radionuclide is measured immediately prior to injecting it into organism of patient as well as average intensiveness of radiation from focuses having absorbed radionuclide, and after that individual relative dose of open radionuclide injected into pathologic focuses is computed using formula

where Dn/o - value of relative dose in %, Io - original intensiveness of radiation at the moment of injection of radionuclide, In - average intensiveness of radiation from focuses at day or hour of measurement of n, B0 and Bn - background values of radiation intensiveness at the moment of injection of radionuclide and at the day of measurement, respectively, k - coefficient of daily or hourly decomposition of radionuclide, n - number of days or hours having passed since the moment of injection of radionuclide.

EFFECT: invention allows verification of relative dose in most precise and individual manner.

3 ex

FIELD: medical facilities.

SUBSTANCE: device can be used as a tool for malignant tumors surgery. Device for radionuclide surgery has gamma radiation detector, collimator and handle. Wire of detector is connected with measuring unit. Gamma radiation detector is fixed in metal tip with sharpened side edge, which passes in plane being perpendicular to optical axis of gamma radiation detector. Detector is made in form of semiconductor crystal; two collimators adjoin opposite surfaces of crystal. Collimators have cells which pass in parallel to optical axis of gamma detector. Measuring unit has electronic circuit with sonic signal source.

EFFECT: ability of reaching area of lesion for removing it.

4 cl, 2 dwg

FIELD: medicine.

SUBSTANCE: device belongs to wide spectrum of influence devices, which is able to make prophylactic and medicinal influence onto human body; in particular, it can be used for destroying benign and malignant tumors and other concentrated formations. Device for making physiotherapeutic effect has control unit and influence localization unit connected with influence localization area. It also has hard base and unit for movement along x, y and z coordinates. Physiotherapeutic device is made in form of frame mounted onto hard base for shift in linear coordinates x, y and z, and n physiotherapeutic influence sources. The sources are disposed along perimeter of frame, which frame is connected mechanically with corresponding outputs of shift unit along coordinates x, y and z. Inputs o shift unit are connected with corresponding outputs along coordinates x, y and z of control unit. Corresponding inputs of control unit are connected with additional outputs of shift unit along coordinates x, y and z. Control input of control unit is connected with output of influence localization unit.

EFFECT: improved efficiency of physiotherapeutic effect; reduced negative reactions of organs and tissues surrounding the area.

13 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves administering Wobenzyme combined with brachytherapy with radiomodification and transpupillary thermotherapy or combined with isolated transpupillary thermotherapy. When combined with brachytherapy with radiomodification, Wobenzyme is given 2 days before brachytherapy at a dose of 3 pills 3 times a day with the exception of 8 h before fixation and removal of β-applicator. Next to it, Wobenzyme is given at a dose of 4-6 pills 3 times a day during 3 months. Then, the dose is reduced by 2 pills every month at the fourth, fifth and sixth months. Adjuvant transpupillary thermotherapy is carried out 6 months later after brachytherapy. Wobenzyme is given at a dose of 2-3 pills 3 times a day 2 days before transpupillary thermotherapy. Then, the dose is 4-6 pills 3 times a day during 2 months with following dose reduction by 3 pills every month to prophylactic dose of 1 pill a day. When carrying out isolated transpupillary thermotherapy, Wobenzyme is given in the same mode that it was the case when carrying out adjuvant transpupillary thermotherapy after brachytherapy. To prevent metastasis occurrence, Wobenzyme administration is continued at a dose of 1 pill 7 days every month during the first year and at a dose of 1 pill 3 days every month during the second observation year.

EFFECT: accelerated resorption processes; reduced risk of radiation treatment complications.

FIELD: medicine, oncology.

SUBSTANCE: one should carry out radiation therapy with quick neutrons 6.3 Mev twice weekly in two stages: at the first stage it is necessary to prescribe 3-4 seances of neutron therapy at interval of 48-72 h directly onto area of tumoral relapse and onto surrounding normal tissues at the distance of about 3-5 cm against tumoral foci, single focal dosage being 1.6-2.0 Gy, relative biological efficiency corresponds to 2.91-2.79, onto the skin - 2.0-2.2 Gy, up to total focal dosage being 6.6±1.5 Gy, onto the skin - 8.3±1.3 Gy, at the second stage it is necessary to carry out gamma- or electronic therapy at single focal dosage being 2.0-3.0 Gy, 5 fractions weekly, moreover, total course dosage of neutron-photon irradiation per a focus corresponds to 60 Gy by isoeffect at duration of irradiation course of about 20-25 d.

EFFECT: higher efficiency of therapy.

2 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: assembly can be used for revealing pathologic cells when determining elemental composition of matter from gamma-radiation, for example, from 59Fe isotope stored in mammal gland. Gamma-spectrometry assembly for inspection of mammal gland has patient's chair, collimators, radiation protection, drives for moving chair, spectrometer, ionizing radiation detectors and control board. Collimators are disposed in radiation protection aid and they are made of material which well absorbs ionizing radiation. Collimators are mounted for direction of radiation onto ionizing radiation detectors. Collimators and ionizing radiation detectors are mounted in unit with cavities in form of cups for placing objects to be tested.

EFFECT: improved radiation safety.

2 cl, 3 dwg

FIELD: medicine, ophthalmology.

SUBSTANCE: before the onset of protonotherapy one should surgically withdraw eyelids beyond bony orbital borders for the purpose of complete prevention of complications associated with blepharoirradiation at conducting protonotherapy and creating conditions for the next valuable prosthetics. Thus, after external canthotomy one should make two through vertical incisions of the upper eyelid up to bony orbital border at developing a P-shaped fragment of the upper eyelid, moreover, internal incision should be made about 2-3 mm laterally against the upper lacrimal point, and external one - against internal edge of canthotomic incision. Then one should apply per one P-shaped suture onto both external and internal angles of the fragment, moreover, it is necessary to puncture in needles from cutaneous side of the fragment by applying ligatures in palpebral thickness at capturing a cartilage and perform punctures out into intramarginal space. Similarly, one should apply a single similar P-shaped suture onto the lower eyelid in area of its middle part. The ends of P-shaped sutures should be fixed without tightening frontal and buccal skin, correspondingly. Before carrying out the seance of protonotherapy it is necessary to tighten sutures till eyelids come beyond bony orbital borders, and on finishing the seance of protonotherapy sutures should be weakened till the moment of palpebral juncture.

EFFECT: higher efficiency of prophylaxis.

1 cl, 1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: method involves mixing patient liquor with 3 ml of 10% albumin solution, with chemopreparation and incubating. Then, the mixture is introduced via catheter into subarchnoid space. Repeated introduction is carried out 7 days later.

EFFECT: alleviated intracranial hypertension phenomena in cases of endolumbal drugs introduction; reduced risk of toxic complications.

Up!